Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.Pharmaceutical giant Pfizer (PFE -0.31%) has long been a player in the healthcare industry, but it's currently experiencing a bit of a hangover. Pfizer's business rapidly expanded during the COVID-19 pandemic, thanks to a temporary growth spurt from selling Comirnaty (its COVID-19 vaccine) and Paxlovid (its antiviral therapy for COVID-19).But those sales have fallen dramatically as pandemic pressur ...